Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2019;6:11–21. doi:10.2147/JHC.S159805
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307–319. doi:10.1016/j.jhep.2019.09.025
   PubMed Web of Science ®Google Scholar
• Yao C, Wu S, Kong J, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biol Med. 2023;20(1):25–43. doi:10.20892/j.issn.2095-3941.2022.0449
   PubMed Web of Science ®Google Scholar
• Thomas MB, Garrett-Mayer E, Anis M, et al. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology. 2018;94(6):329–339. doi:10.1159/000485384
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Bao MH, Wong CC. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells. 2021;10(7). doi:10.3390/cells10071715
   Web of Science ®Google Scholar
• Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12(2):558–580. doi:10.1016/j.apsb.2021.09.019
   PubMed Web of Science ®Google Scholar
• Foglia B, Beltra M, Sutti S, Cannito S. Metabolic Reprogramming of HCC: a New Microenvironment for Immune Responses. Int J Mol Sci. 2023;24(8). doi:10.3390/ijms24087463
   Web of Science ®Google Scholar
• Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115(24):5651–5661. doi:10.1002/cncr.24687
   PubMed Web of Science ®Google Scholar
• Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X, Calvisi DF. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Front Oncol. 2019;9:1412. doi:10.3389/fonc.2019.01412
   PubMed Web of Science ®Google Scholar
• Feng XC, Liu FC, Chen WY, Du J, Liu H. Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy. World J Gastrointest Oncol. 2023;15(4):617–631. doi:10.4251/wjgo.v15.i4.617
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–777. doi:10.1038/nrc2222
   PubMed Web of Science ®Google Scholar
• Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. Oncogenesis. 2023;12(1):16. doi:10.1038/s41389-023-00460-8
   PubMed Web of Science ®Google Scholar
• Hao Q, Li T, Zhang X, et al. Expression and roles of fatty acid synthase in hepatocellular carcinoma. Oncol Rep. 2014;32(6):2471–2476. doi:10.3892/or.2014.3484
   PubMed Web of Science ®Google Scholar
• Sun H, Wang F, Huang Y, et al. Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma. J Cancer. 2022;13(3):951–964. doi:10.7150/jca.52778
   PubMed Web of Science ®Google Scholar
• Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013;144(5):1066–1075 e1. doi:10.1053/j.gastro.2013.01.054
   PubMed Web of Science ®Google Scholar
• Hac-Wydro K, Jedrzejek K, Dynarowicz-Latka P. Effect of saturation degree on the interactions between fatty acids and phosphatidylcholines in binary and ternary Langmuir monolayers. Colloids Surf B Biointerfaces. 2009;72(1):101–111. doi:10.1016/j.colsurfb.2009.03.019
   PubMed Web of Science ®Google Scholar
• Liu HH, Xu Y, Li CJ, et al. An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming. Mol Ther. 2022;30(7):2554–2567. doi:10.1016/j.ymthe.2022.03.015
   PubMed Web of Science ®Google Scholar
• Luo X, Zheng E, Wei L, et al. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 2021;12(4):328. doi:10.1038/s41419-021-03596-w
   PubMed Web of Science ®Google Scholar
• Hao JW, Wang J, Guo H, et al. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020;11(1):4765. doi:10.1038/s41467-020-18565-8
   PubMed Web of Science ®Google Scholar
• Helms JB, Zurzolo C. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic. 2004;5(4):247–254. doi:10.1111/j.1600-0854.2004.0181.x
   PubMed Web of Science ®Google Scholar
• Donatello S, Babina IS, Hazelwood LD, Hill AD, Nabi IR, Hopkins AM. Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration. Am J Pathol. 2012;181(6):2172–2187. doi:10.1016/j.ajpath.2012.08.025
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology. 2009;50(1):175–184. doi:10.1002/hep.22941
   PubMed Web of Science ®Google Scholar
• Kawata S, Takaishi K, Nagase T, et al. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 1990;50(11):3270–3273.
   PubMed Web of Science ®Google Scholar
• Che L, Chi W, Qiao Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69(1):177–186. doi:10.1136/gutjnl-2018-317581
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen L, Sun B, et al. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway. Mol Metab. 2021;51:101230. doi:10.1016/j.molmet.2021.101230
   PubMed Web of Science ®Google Scholar
• Cui Y, Liang S, Zhang S, et al. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res. 2020;39(1):90. doi:10.1186/s13046-020-01591-1
   PubMed Web of Science ®Google Scholar
• Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and −2. Curr Opin Lipidol. 2001;12(3):289–296. doi:10.1097/00041433-200106000-00008
   PubMed Web of Science ®Google Scholar
• Schlaepfer IR, Joshi M. CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential. Endocrinology. 2020;161(2). doi:10.1210/endocr/bqz046
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Nakagawa H, Enooku K, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018;67(8):1493–1504. doi:10.1136/gutjnl-2017-315193
   PubMed Web of Science ®Google Scholar
• Huang J, Viswakarma N, Yu S, et al. Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice. Am J Pathol. 2011;179(2):703–713. doi:10.1016/j.ajpath.2011.04.030
   PubMed Web of Science ®Google Scholar
• Li X, Li C, Zhang L, et al. The significance of exosomes in the development and treatment of hepatocellular carcinoma. Mol Cancer. 2020;19(1):1. doi:10.1186/s12943-019-1085-0
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129–3140. doi:10.1158/1535-7163.MCT-08-0013
   PubMed Web of Science ®Google Scholar
• Chen J, Jin R, Zhao J, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015;367(1):1–11. doi:10.1016/j.canlet.2015.06.019
   PubMed Web of Science ®Google Scholar
• Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87. doi:10.1038/s41392-020-0187-x
   PubMed Web of Science ®Google Scholar
• Mendez-Blanco C, Fondevila F, Garcia-Palomo A, Gonzalez-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50(10):1–9. doi:10.1038/s12276-018-0159-1
   PubMed Web of Science ®Google Scholar
• Bort A, Sanchez BG, de Miguel I, Mateos-Gomez PA, Diaz-Laviada I. Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells. Mol Biol Rep. 2020;47(4):2635–2647. doi:10.1007/s11033-020-05352-3
   PubMed Web of Science ®Google Scholar
• MKF M, Lau EYT, Leung DHW, et al. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J Hepatol. 2017;67(5):979–990. doi:10.1016/j.jhep.2017.06.015
   PubMed Web of Science ®Google Scholar
• Gao Q, Zhang G, Zheng Y, et al. SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC. Cell Death Differ. 2020;27(3):1086–1104. doi:10.1038/s41418-019-0399-1
   PubMed Web of Science ®Google Scholar
• Suk FM, Wang YH, Chiu WC, et al. Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma. Int J Mol Sci. 2021;22(16). doi:10.3390/ijms22168567
   Web of Science ®Google Scholar
• Yue X, Kong Y, Zhang Y, et al. SREBF2-STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. Cancer Sci. 2023;114(2):477–489. doi:10.1111/cas.15449
   PubMed Web of Science ®Google Scholar
• Zheng C, Zhu Y, Liu Q, Luo T, Xu W. Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1. Front Pharmacol. 2021;12:689767. doi:10.3389/fphar.2021.689767
   PubMed Web of Science ®Google Scholar
• Fu R, Jiang S, Li J, Chen H, Zhang X. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. Med Oncol. 2020;37(4):24. doi:10.1007/s12032-020-01350-4
   PubMed Web of Science ®Google Scholar
• Fang T, Jiao Z, You Y, et al. Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1. Biochem Pharmacol. 2023;210:115489. doi:10.1016/j.bcp.2023.115489
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu J, Du Q, Yan Y, Geller DA. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating beta-catenin. Transl Oncol. 2021;14(6):101059. doi:10.1016/j.tranon.2021.101059
   PubMed Web of Science ®Google Scholar
• Zhao Z, Song J, Zhang D, Wu F, Tu J, Ji J. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sci. 2021;264:118642. doi:10.1016/j.lfs.2020.118642
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang D, Wu F, et al. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med. 2021;25(1):549–560. doi:10.1111/jcmm.16108
   PubMed Web of Science ®Google Scholar
• Sun D, Liu J, Wang Y, Dong J. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Front Oncol. 2022;12:944537. doi:10.3389/fonc.2022.944537
   PubMed Web of Science ®Google Scholar
• Li B, Qin Y, Yu X, Xu X, Yu W. Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis. Cell Prolif. 2022;55(1):e13167. doi:10.1111/cpr.13167
   PubMed Web of Science ®Google Scholar
• Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17(1):25. doi:10.1186/s12943-018-0775-3
   PubMed Web of Science ®Google Scholar
• Hu B, Zou T, Qin W, et al. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Res. 2022;82(20):3845–3857. doi:10.1158/0008-5472.CAN-21-4140
   PubMed Web of Science ®Google Scholar
• Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595(7869):730–734. doi:10.1038/s41586-021-03741-7
   PubMed Web of Science ®Google Scholar
• Mok EHK, Leung CON, Zhou L, et al. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma. Cancer Res. 2022;82(17):3102–3115. doi:10.1158/0008-5472.CAN-21-2934
   PubMed Web of Science ®Google Scholar
• Mendelson K, Evans T, Hla T. Sphingosine 1-phosphate signalling. Development. 2014;141(1):5–9. doi:10.1242/dev.094805
   PubMed Web of Science ®Google Scholar
• Wang X, Qiu Z, Dong W, et al. S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression. Cell Death Dis. 2022;13(9):768. doi:10.1038/s41419-022-05210-z
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–4300. doi:10.1200/JCO.2005.01.3441
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:41. doi:10.1186/1741-7015-7-41
   PubMed Web of Science ®Google Scholar
• Shi T, Iwama H, Fujita K, et al. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci. 2021;22(23). doi:10.3390/ijms222313071
   Web of Science ®Google Scholar
• Calvisi DF, Wang C, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140(3):1071–1083. doi:10.1053/j.gastro.2010.12.006
   PubMed Web of Science ®Google Scholar
• Jiang X, Huang L, Xing D. Photoactivation of Dok1/ERK/PPARgamma signaling axis inhibits excessive lipolysis in insulin-resistant adipocytes. Cell Signal. 2015;27(7):1265–1275. doi:10.1016/j.cellsig.2015.03.010
   PubMed Web of Science ®Google Scholar
• Srimuninnimit V, Sriuranpong V, Suwanvecho S. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. Asia Pac J Clin Oncol. 2014;10(3):255–260. doi:10.1111/ajco.12191
   PubMed Web of Science ®Google Scholar
• Ouyang T, Kan X, Zheng C. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: monotherapies and Combined Therapies. Front Oncol. 2022;12:898964. doi:10.3389/fonc.2022.898964
   PubMedGoogle Scholar
• Angeles TS, Hudkins RL. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors. Expert Opin Drug Discov. 2016;11(12):1187–1199. doi:10.1080/17460441.2016.1245286
   PubMed Web of Science ®Google Scholar
• Shueng PW, Chan HW, Lin WC, Kuo DY, Chuang HY. Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism. Int J Mol Sci. 2022;23(12). doi:10.3390/ijms23126501
   Web of Science ®Google Scholar
• Jones SF, Infante JR. Molecular Pathways: fatty Acid Synthase. Clin Cancer Res. 2015;21(24):5434–5438. doi:10.1158/1078-0432.CCR-15-0126
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou Y, Xu H, et al. Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology. 2022;76(4):951–966. doi:10.1002/hep.32359
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Caulfield TR, Marlow L, et al. Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget. 2018;9(1):3–20. doi:10.18632/oncotarget.21545
   PubMedGoogle Scholar
• Liu G, Kuang S, Cao R, Wang J, Peng Q, Sun C. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway. FASEB J. 2019;33(9):10089–10103. doi:10.1096/fj.201802619RR
   PubMed Web of Science ®Google Scholar
• Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Theranostics. 2019;9(17):4893–4908. doi:10.7150/thno.36037
   PubMed Web of Science ®Google Scholar
• Kuda O, Pietka TA, Demianova Z, et al. Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages. J Biol Chem. 2013;288(22):15547–15555. doi:10.1074/jbc.M113.473298
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Harb W, Patnaik A, et al. 374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 2020;8(Suppl 3):A228–A228. doi:10.1136/jitc-2020-SITC2020.0374
   Google Scholar
• Feng WW, Zuppe HT, Kurokawa M. The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target. Cells. 2023;12(12). doi:10.3390/cells12121605
   Web of Science ®Google Scholar
• Wei J, Leit S, Kuai J, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature. 2019;568(7753):566–570. doi:10.1038/s41586-019-1094-6
   PubMed Web of Science ®Google Scholar
• Granchi C. ATP citrate lyase (ACLY) inhibitors: an anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem. 2018;157:1276–1291. doi:10.1016/j.ejmech.2018.09.001
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhou Q, Zhao C, Li J, Yu Z, Zhu Q. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2alpha/ATF4/CHOP axis. J Cell Mol Med. 2021;25(3):1468–1479. doi:10.1111/jcmm.16235
   PubMed Web of Science ®Google Scholar
• Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol. 2013;28(6):485–492. doi:10.1007/s10654-013-9806-y
   PubMed Web of Science ®Google Scholar
• Feng J, Dai W, Mao Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha/PPAR-gamma/PKM2-mediated glycolysis. J Exp Clin Cancer Res. 2020;39(1):24. doi:10.1186/s13046-020-1528-x
   PubMed Web of Science ®Google Scholar
• Jouve JL, Lecomte T, Bouche O, et al. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(3):516–522. doi:10.1016/j.jhep.2019.04.021
   PubMed Web of Science ®Google Scholar
• Mullard A. Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021;20(4):247–250. doi:10.1038/d41573-021-00052-4
   PubMed Web of Science ®Google Scholar
• Burslem GM, Crews CM. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell. 2020;181(1):102–114. doi:10.1016/j.cell.2019.11.031
   PubMed Web of Science ®Google Scholar
• Bayon-Cordero L, Alkorta I, Arana L. Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs. Nanomaterials (Basel). 2019;9(3). doi:10.3390/nano9030474
   Google Scholar
• Shashkovskaya VS, Vetosheva PI, Shokhina AG, et al. Delivery of Lipid Nanoparticles with ROS Probes for Improved Visualization of Hepatocellular Carcinoma. Biomedicines. 2023;11(7). doi:10.3390/biomedicines11071783
   PubMed Web of Science ®Google Scholar
• Cichoz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014;20(25):8082–8091. doi:10.3748/wjg.v20.i25.8082
   PubMed Web of Science ®Google Scholar
• Ren W, Jhala US, Du K. Proteomic analysis of protein palmitoylation in adipocytes. Adipocyte. 2013;2(1):17–28. doi:10.4161/adip.22117
   PubMedGoogle Scholar
• Chamberlain LH, Shipston MJ. The physiology of protein S-acylation. Physiol Rev. 2015;95(2):341–376. doi:10.1152/physrev.00032.2014
   PubMed Web of Science ®Google Scholar
• Gottlieb CD, Linder ME. Structure and function of DHHC protein S-acyltransferases. Biochem Soc Trans. 2017;45(4):923–928. doi:10.1042/BST20160304
   PubMed Web of Science ®Google Scholar
• Lawrence DS, Zilfou JT, Smith CD. Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors. J Med Chem. 1999;42(24):4932–4941. doi:10.1021/jm980591s
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Vasudevan A, Linder ME, Deschenes RJ. Protein palmitoylation by a family of DHHC protein S-acyltransferases. J Lipid Res. 2006;47(6):1118–1127. doi:10.1194/jlr.R600007-JLR200
   PubMed Web of Science ®Google Scholar
• Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. Nat Rev Mol Cell Biol. 2007;8(1):74–84. doi:10.1038/nrm2084
   PubMed Web of Science ®Google Scholar
• Wang J, Hao JW, Wang X, et al. DHHC4 and DHHC5 Facilitate Fatty Acid Uptake by Palmitoylating and Targeting CD36 to the Plasma Membrane. Cell Rep. 2019;26(1):209–221 e5. doi:10.1016/j.celrep.2018.12.022
   PubMed Web of Science ®Google Scholar
• Zhou B, Wang Y, Zhang L, et al. The palmitoylation of AEG-1 dynamically modulates the progression of hepatocellular carcinoma. Theranostics. 2022;12(16):6898–6914. doi:10.7150/thno.78377
   PubMed Web of Science ®Google Scholar
• Grzesk G, Dorota B, Wolowiec Ł, et al. Safety of PCSK9 inhibitors. Biomed Pharmacother. 2022;156:113957. doi:10.1016/j.biopha.2022.113957
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang H, Meng J, et al. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. Cell Rep. 2022;40(7):111194. doi:10.1016/j.celrep.2022.111194
   PubMed Web of Science ®Google Scholar
• Davda D, El Azzouny MA, Tom CTMB, et al. Profiling targets of the irreversible palmitoylation inhibitor 2-bromopalmitate. ACS Chem Biol. 2013;8(9):1912–1917. doi:10.1021/cb400380s
   PubMed Web of Science ®Google Scholar
• Lemonidis K, Salaun C, Kouskou M, Diez-Ardanuy C, Chamberlain LH, Greaves J. Substrate selectivity in the zDHHC family of S-acyltransferases. Biochem Soc Trans. 2017;45(3):751–758. doi:10.1042/BST20160309
   PubMed Web of Science ®Google Scholar
• Stolk DA, Horrevorts SK, Schetters STT, et al. Palmitoylated antigens for the induction of anti-tumor CD8(+) T cells and enhanced tumor recognition. Mol Ther Oncolytics. 2021;21:315–328. doi:10.1016/j.omto.2021.04.009
   PubMed Web of Science ®Google Scholar
• Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88. doi:10.1038/s41419-020-2298-2
   PubMed Web of Science ®Google Scholar
• Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054–2081. doi:10.1080/15548627.2020.1810918
   PubMed Web of Science ®Google Scholar
• Bai Y, Meng L, Han L, et al. Lipid storage and lipophagy regulates ferroptosis. Biochem Biophys Res Commun. 2019;508(4):997–1003. doi:10.1016/j.bbrc.2018.12.039
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273–285. doi:10.1016/j.cell.2017.09.021
   PubMed Web of Science ®Google Scholar
• Magtanong L, Ko PJ, To M, et al. Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. Cell Chem Biol. 2019;26(3):420–432 e9. doi:10.1016/j.chembiol.2018.11.016
   PubMed Web of Science ®Google Scholar
• Louandre C, Ezzoukhry Z, Godin C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int, J, Cancer. 2013;133(7):1732–1742. doi:10.1002/ijc.28159
   PubMed Web of Science ®Google Scholar
• Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. doi:10.1007/s13238-020-00789-5
   PubMed Web of Science ®Google Scholar
• Li Y, Yang W, Zheng Y, et al. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res. 2023;42(1):6. doi:10.1186/s13046-022-02567-z
   PubMed Web of Science ®Google Scholar
• Iseda N, Itoh S, Toshida K, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. Cancer Sci. 2022;113(7):2272–2287. doi:10.1111/cas.15378
   PubMed Web of Science ®Google Scholar
• Sun X, Niu X, Chen R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64(2):488–500. doi:10.1002/hep.28574
   PubMed Web of Science ®Google Scholar
• Lai Y, Lu N, Luo S, Wang H, Zhang P. A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption. J Med Chem. 2022;65(19):13041–13051. doi:10.1021/acs.jmedchem.2c00880
   PubMed Web of Science ®Google Scholar
• Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013;65:750–764. doi:10.1016/j.freeradbiomed.2013.06.041
   PubMed Web of Science ®Google Scholar
• Zheng A, Chevalier N, Calderoni M, et al. CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma. Oncotarget. 2019;10(66):7058–7070. doi:10.18632/oncotarget.27361
   PubMedGoogle Scholar
• Lai HY, Tsai HH, Yen CJ, et al. Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation. Front Cell Dev Biol. 2020;8:596655. doi:10.3389/fcell.2020.596655
   PubMed Web of Science ®Google Scholar
• Feng J, Lu H, Ma W, et al. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. Protein Cell. 2022;13(11):825–841. doi:10.1007/s13238-022-00906-6
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhan P, Lu J, et al. Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway. Liver Int. 2023;43(7):1577–1592. doi:10.1111/liv.15611
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhou H, Li A, et al. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. Aging. 2021;13(18):22120–22133. doi:10.18632/aging.203464
   PubMedGoogle Scholar
• Misra JR, Irvine KD. The Hippo Signaling Network and Its Biological Functions. Annu Rev Genet. 2018;52:65–87. doi:10.1146/annurev-genet-120417-031621
   PubMed Web of Science ®Google Scholar
• Han S, Lim JY, Cho K, et al. Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). Cancers (Basel). 2022;14(11). doi:10.3390/cancers14112733
   Web of Science ®Google Scholar
• Chen L, Yang Z, Cao Y, et al. Pan-cancer analysis and single-cell analysis revealed the role of ABCC5 transporter in hepatocellular carcinoma. Channels. 2021;15(1):541–554. doi:10.1080/19336950.2021.1968592
   PubMed Web of Science ®Google Scholar
• Huang W, Chen K, Lu Y, et al. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma. Neoplasia. 2021;23(12):1227–1239. doi:10.1016/j.neo.2021.11.002
   PubMed Web of Science ®Google Scholar
• Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447(7146):864–868. doi:10.1038/nature05859
   PubMed Web of Science ®Google Scholar
• Jing W, Shuo L, Yingru X, et al. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019;519(1):41–45. doi:10.1016/j.bbrc.2019.08.115
   PubMed Web of Science ®Google Scholar
• Tang B, Zhu J, Li J, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Commun Signal. 2020;18(1):174. doi:10.1186/s12964-020-00663-1
   PubMed Web of Science ®Google Scholar